You are here: Industry Insights > Vir Biotechnology

News List

GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab WorldPharmaNews
January 17, 2022
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) announced that the US Government will purchase an additional 600,000 doses of sotrovimab...
GSK, Vir say final data confirm efficacy of recently authorised COVID-19 antibody sotrovimab firstwordpharma
June 22, 2021
GlaxoSmithKline and Vir Biotechnology on Monday reported final results from the Phase III COMET-ICE trial confirming that early use of sotrovimab significantly reduces hospitalisation and death in COVID-19 outpatients at high risk of worsening to severe
Gilead and Vir unite to find a ‘functional cure’ for hepatitis B pharmatimes
January 15, 2021
Gilead Sciences and Vir Biotechnology have partnered to evaluate novel therapeutic combination strategies aimed at developing a ‘functional cure’ for chronic hepatitis B virus (HBV).
GSK, Vir Biotechnology to evaluate neutralising Covid-19 antibody in AGILE study pharmaceutical-business-review
January 14, 2021
GlaxoSmithKline, along with Vir Biotechnology, has agreed with the UK-based AGILE initiative to assess VIR-7832 in patients with mild to moderate Covid-19 in a phase 1b/2a clinical study.
Vir Biotechnology and GSK announce start of NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19 worldpharmanews
December 21, 2020
Vir Biotechnology, Inc. and GlaxoSmithKline plc announced that the first patient has been dosed in a new sub-trial of the National Institutes of Health's (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Program Phase 3 ...
Vir Biotech research highlights mechanism to enhance monoclonal antibodies for inducing protective response expresspharma
October 10, 2020
The research published in Nature focuses on the role of the Fc domain of monoclonal antibodies, regions with the capacity to bind to other immune cells through a family of receptors.
Vir Biotechnology and GSK start phase 2/3 study of COVID-19 antibody treatment worldpharmanews
September 01, 2020
Vir Biotechnology, Inc. and GlaxoSmithKline plc announced that the first patient was dosed last week in a phase 2/3 study with VIR-7831 (also known as GSK4182136), a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) ...
Vir, Alnylam to develop VIR-2703 RNAi therapeutic candidate for Covid-19 treatment pharmaceutical-business-review
May 08, 2020
Vir Biotechnology and Alnylam Pharmaceuticals said that they have selected an investigational RNAi therapeutic called VIR-2703 which will be developed for targeting the SARS-CoV-2 genome for the treatment of Covid-19 (novel coronavirus).
Vir selects Samsung Biologics to produce Covid-19 antibodies pharmaceutical-technology
April 14, 2020
Immunology company Vir Biotechnology has selected South Korea-based Samsung Biologics for large-scale production of antibodies to potentially treat Covid-19.
Samsung Biologics and Vir Biotechnology Enter into Agreement for Large Scale Manufacture of SARS-COV-2 Antibodies for Potential COVID-19 Treatment fiercepharma
April 13, 2020
Samsung Biologics (207940.KS) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services for Vir's SARS-CoV-2 monoclonal antibody (mAb) program.

Previous page 1 2 Next page